Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
70
Employees70
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
70
Employees70

SVRA Key Statistics

Market cap
1.01B
Market cap1.01B
Price-Earnings ratio
-8.79
Price-Earnings ratio-8.79
Dividend yield
Dividend yield
Average volume
1.28M
Average volume1.28M
High today
High today
Low today
Low today
Open price
$5.05
Open price$5.05
Volume
3.35K
Volume3.35K
52 Week high
$7.01
52 Week high$7.01
52 Week low
$1.89
52 Week low$1.89

Stock Snapshot

The current Savara(SVRA) stock price is $4.96, with a market capitalization of 1.01B. The stock trades at a price-to-earnings (P/E) ratio of -8.79.

During the trading day, Savara(SVRA) stock saw an opening price of $5.05, a peak of —, and a bottom of —.

Trading activity shows a volume of 3.35K, compared to an average daily volume of 1.28M.

Over the past 52 weeks, Savara(SVRA) stock has traded between a high of $7.01 and a low of $1.89.

Over the past 52 weeks, Savara(SVRA) stock has traded between a high of $7.01 and a low of $1.89.

SVRA News

Simply Wall St 1d
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA?

Savara Inc. has reported its first-quarter 2026 results, recording a net loss of US$37.28 million, compared with US$26.64 million a year earlier, and a basic lo...

Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA?
Simply Wall St 3d
A Look At Savara Valuation As MOLBREEVI Advances And Q1 2026 Results Highlight Cash And Funding Plan

Savara (SVRA) stock is in focus after the company reported a Q1 2026 net loss of US$37.3 million and highlighted key regulatory milestones and funding plans tie...

A Look At Savara Valuation As MOLBREEVI Advances And Q1 2026 Results Highlight Cash And Funding Plan
TipRanks 7d
Savara reports Q1 EPS (15c), consensus (14c)

“With approximately $203M in cash and, upon MOLBREEVI approval, access to up to an additional $150Min non-dilutive capital through debt and royalty structures,...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.